Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances

PLUS THERAPEUTICS, INC.

2025-Q3 EPS reported -$0.29 revenue$3,846,000

Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.
Cash and investments $16.6M (up from $6.9M on June 30, 2025 and $3.6M at Dec 31, 2024).
First national coverage agreement with UnitedHealthcare for CNSide diagnostics, covering 51M+ lives.
Houston lab received CLIA certification, enabling Medicare/Medicaid access and commercial payor coverage.
Positive ReSPECT-LM Phase 1 results for REYOBIQ presented at SNO/ASCO; advance payment of $1.9M from CPRIT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.